posted on 2022-02-11, 16:38authored byAnna Parviainen, Taina Härkönen, Jorma Ilonen, Anna But, Mikael Knip, the Finnish Pediatric Diabetes Register
OBJECTIVE
<p>Previous
findings suggest that there are age-related endotypes of type 1 diabetes with
different underlying etiopathological mechanisms in those diagnosed < 7
years compared with those diagnosed ≥ 13 years. We set out to explore whether variation
in demographic, clinical, autoimmune and genetic characteristics of children and
adolescents with newly diagnosed type 1 diabetes support the existence of these
proposed endotypes. </p>
<p>RESEARCH DESIGN AND METHODS</p>
<p>We
used data from the Finnish Pediatric Diabetes Register to analyze
characteristics of 6015 children and adolescents diagnosed with type 1 diabetes
between 2003 and 2019. We described and compared demographic data, clinical
characteristics at diagnosis, autoantibody profile and HLA class II associated
disease risk between three groups formed based on age at diagnosis; <7, 7–12
and ≥13 years. </p>
<p>RESULTS</p>
<p>We
found significant age-related differences in most of the characteristics
analyzed. Children diagnosed < 7 years were characterized by a higher prevalence
of affected first-degree relatives, stronger HLA-conferred disease susceptibility,
and higher number of autoantibodies at diagnosis, in particular a higher
frequency of insulin autoantibodies, when compared to older children. Those
diagnosed ≥ 13 years had a considerably higher male preponderance, a higher
frequency of glutamic acid decarboxylase autoantibodies, longer duration of
symptoms before diagnosis and more severe metabolic decompensation, reflected
e.g. by a higher frequency of diabetic ketoacidosis.</p>
<p>CONCLUSIONS</p>
<p>Our
findings suggest that the heterogeneity of type 1 diabetes is associated with the
underlying disease process, and support the existence of distinct endotypes of
type 1 diabetes related to age at diagnosis.</p>
Funding
The study was supported by the Academy of Finland (Decision number 292538), the Sigrid Jusélius Foundation, Finska Läkaresällskapet and the Liv and Hälsa Fund.